ConductScience.org, home

Paper41821152

Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio-Immunotherapy.

Zhang W and 8 others. Adv Sci (Weinh), 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio-Immunotherapy. Papers, record 41821152. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41821152

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Engineering MnPt Bimetallic Nanozymes for Cascade Enzymatic Therapy and Enhanced Radio-Immunotherapy.
PubMed
Journal
Adv Sci (Weinh)
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-08-13
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang WWenyihttps://orcid.org/0009-0000-9641-4248
2Guo YYangyang
3Xu GGuoping
4Liu LLuhaoxiang
5Chen LLin
6Zhang CCai
7Li YYiming
8Li JJianmin
9Zhao YYanghttps://orcid.org/0000-0003-4656-172X

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PlatinumMajor topic
RadioimmunotherapyMajor topic
ManganeseMajor topic
ImmunotherapyMajor topic
Breast NeoplasmsMajor topic
Animals
Mice
Humans
Tumor Microenvironment
Female
Manganese Compounds
cGAS-STING Signaling Pathway
Cell Line, Tumor
Hyaluronic Acid
Oxides

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82272804National Natural Science Foundation of ChinaPubMed
91959114National Natural Science Foundation of ChinaPubMed
81872106National Natural Science Foundation of ChinaPubMed
22JCQNJC01700Natural Science Foundation of TianjinPubMed
TJWJ2022XK015Scientific and Technological Research Program of Tianjin Health CommissionPubMed
TJYXZDXK-070CMedical Key Discipline Program of Tianjin Municipal Healthcare CommissionPubMed

Source PubMed

Download CSV of grants

References58

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136848115Biomineralized MnO2 Nanoplatforms Mediated Delivery of Immune Checkpoint Inhibitors with STING Pathway Activation to Potentiate Cancer Radio-Immunotherapy.ACS Nano2023https://conductscience.org/library/papers/36848115PubMed
240367177Endogenous/exogenous dual-responsive nanozyme for photothermally enhanced ferroptosis-immune reciprocal synergistic tumor therapy.Sci Adv2025https://conductscience.org/library/papers/40367177PubMed
332239210
Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer.
JAMA Oncol2020https://conductscience.org/library/papers/32239210PubMed
438971872An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses.Nat Commun2024https://conductscience.org/library/papers/38971872PubMed
533009382Targeted scavenging of extracellular ROS relieves suppressive immunogenic cell death.Nat Commun2020https://conductscience.org/library/papers/33009382PubMed
638193384An Immunocompetent Hafnium Oxide-Based STING Nanoagonist for Cancer Radio-immunotherapy.ACS Nano2024https://conductscience.org/library/papers/38193384PubMed
738816668Signaling pathways in liver cancer: pathogenesis and targeted therapy.Mol Biomed2024https://conductscience.org/library/papers/38816668PubMed
839025943Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours.Nat Biomed Eng2024https://conductscience.org/library/papers/39025943PubMed
934099730Glucose-oxidase like catalytic mechanism of noble metal nanozymes.Nat Commun2021https://conductscience.org/library/papers/34099730PubMed
1040525679Tumor Microenvironment-responsive Nanocatalyst for Targeted Chemodynamic Cancer Therapy.Adv Healthc Mater2025https://conductscience.org/library/papers/40525679PubMed
1138777879The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond.Cell Mol Immunol2024https://conductscience.org/library/papers/38777879PubMed
1238063844STING Agonist-Loaded Nanoparticles Promotes Positive Regulation of Type I Interferon-Dependent Radioimmunotherapy in Rectal Cancer.Adv Sci (Weinh)2024https://conductscience.org/library/papers/38063844PubMed
1339571173Oxygen/Nitric Oxide Dual-Releasing Nanozyme for Augmenting TMZ-Mediated Apoptosis and Necrosis.Mol Pharm2025https://conductscience.org/library/papers/39571173PubMed
1432298077Manganese-Based Nanoactivator Optimizes Cancer Immunotherapy via Enhancing Innate Immunity.ACS Nano2020https://conductscience.org/library/papers/32298077PubMed
1536038913Recent advances in therapeutic strategies for triple-negative breast cancer.J Hematol Oncol2022https://conductscience.org/library/papers/36038913PubMed
1640386978Dendrimer-Entrapped CuPt Bimetallic Nanozymes for Tumor Microenvironment-Regulated Photothermal/Catalytic Therapy.ACS Appl Mater Interfaces2025https://conductscience.org/library/papers/40386978PubMed
1741137633Proton-Driven Deformability Enables Nanozyme-Integrated Vaccine for Enhanced Tumor Immunotherapy.Adv Mater2026https://conductscience.org/library/papers/41137633PubMed
1835874717Immunotherapy: Reshape the Tumor Immune Microenvironment.Front Immunol2022https://conductscience.org/library/papers/35874717PubMed
1940810617Nanozyme-Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder-Metastasized Tumors.Adv Mater2025https://conductscience.org/library/papers/40810617PubMed
2034166607Contemporary radiotherapy: present and future.Lancet2021https://conductscience.org/library/papers/34166607PubMed

See all 58 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42884170Nanoparticle-Enabled Immune-Dose Shaping in Breast Cancer Radiotherapy: Reconciling Tumor Immunogenicity with Systemic Immune Preservation.Int J Mol Sci2026https://conductscience.org/library/papers/42884170PubMed
42195458Nanozyme-Driven Signal Amplification in Cancer Biosensing: Innovations Toward Precision and Point-of-Care Oncology.Micromachines (Basel)2026https://conductscience.org/library/papers/42195458PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD44960PubTator's text mininghttps://conductscience.org/library/genes/960NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CGAS115004PubTator's text mininghttps://conductscience.org/library/genes/115004NCBI Gene
STING1340061PubTator's text mininghttps://conductscience.org/library/genes/340061NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41821152

GET https://conductscience.org/api/papers/v1/41821152/references?page=2